New data suggest InterMune Inc.'s intravenous oritavancin is as effective as a regimen of vancomycin plus cephalexin in treating patients with complicated skin and skin-structure infections (CSSSI).
The Weekly Roundup: April 15-19
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events
ReV Up Your Vitiligo Treatment Strategies
Mobile Health Technologies In Studies of Actinic Keratosis Do Not Compromise Patient Safety, Research Article Says
Brittany Scurto, PA-C: How to Discuss an Integrative Medicine Approach With Patients